DK0968182T3 - Hydroxam- og carboxylsyrederivater med MMP- og TNF-inhiberende aktivitet - Google Patents

Hydroxam- og carboxylsyrederivater med MMP- og TNF-inhiberende aktivitet

Info

Publication number
DK0968182T3
DK0968182T3 DK97935666T DK97935666T DK0968182T3 DK 0968182 T3 DK0968182 T3 DK 0968182T3 DK 97935666 T DK97935666 T DK 97935666T DK 97935666 T DK97935666 T DK 97935666T DK 0968182 T3 DK0968182 T3 DK 0968182T3
Authority
DK
Denmark
Prior art keywords
hydroxamic
carboxylic acid
acid derivatives
mmp
inhibitory activity
Prior art date
Application number
DK97935666T
Other languages
English (en)
Inventor
David Alan Owen
John Gary Montana
John Fraser Keily
Robert John Watson
Andrew Douglas Baxter
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616599.8A external-priority patent/GB9616599D0/en
Priority claimed from GBGB9707427.2A external-priority patent/GB9707427D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DK0968182T3 publication Critical patent/DK0968182T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
DK97935666T 1996-08-07 1997-08-07 Hydroxam- og carboxylsyrederivater med MMP- og TNF-inhiberende aktivitet DK0968182T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9616599.8A GB9616599D0 (en) 1996-08-07 1996-08-07 Compounds
GBGB9707427.2A GB9707427D0 (en) 1997-04-11 1997-04-11 Compounds having mmp and tnf inhibitory activity
PCT/GB1997/002129 WO1998005635A1 (en) 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Publications (1)

Publication Number Publication Date
DK0968182T3 true DK0968182T3 (da) 2004-08-16

Family

ID=26309836

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97935666T DK0968182T3 (da) 1996-08-07 1997-08-07 Hydroxam- og carboxylsyrederivater med MMP- og TNF-inhiberende aktivitet

Country Status (17)

Country Link
US (1) US6118001A (da)
EP (1) EP0968182B1 (da)
JP (1) JP2000517297A (da)
KR (1) KR20000029858A (da)
CN (1) CN1227540A (da)
AT (1) ATE266000T1 (da)
AU (1) AU730464B2 (da)
BR (1) BR9711027A (da)
CA (1) CA2263154A1 (da)
CZ (1) CZ297278B6 (da)
DE (1) DE69729007T2 (da)
DK (1) DK0968182T3 (da)
ES (1) ES2217425T3 (da)
NO (1) NO314452B1 (da)
PL (1) PL193829B1 (da)
PT (1) PT968182E (da)
WO (1) WO1998005635A1 (da)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0960096B1 (en) * 1997-01-22 2005-04-06 Aventis Pharmaceuticals Inc. Substituted beta-thiocarboxylic acids
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
KR20000075955A (ko) * 1997-03-04 2000-12-26 죤 에이치. 뷰센 방향족 술포닐 알파-히드록시 히드록삼산 화합물
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6794511B2 (en) * 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
UA66818C2 (uk) 1997-11-21 2004-06-15 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ГІДРОКСИ, АМІНО- ТА ГАЛОПОХІДНІ <font face="Symbol">b</font>-СУЛЬФОНІЛГІДРОКСАМОВИХ КИСЛОТ, ПОХІДНІ ПРОПІОНОВОЇ КИСЛОТИ, СПОСІБ ІНГІБУВАННЯ МАТРИЧНИХ МЕТАЛОПРОТЕЇНАЗ, СПОСІБ ЛІКУВАННЯ ЛЮДИНИ, ЩО СТРАЖДАЄ ВІД АБО ЧУТЛИВОЇ ДО ХВОРОБИ, ПОВ'ЯЗАНОЇ З РУЙНУВАННЯМ СПОЛУЧНОЇ ТКАНИНИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
DK1357109T3 (da) 1998-06-18 2008-09-08 Hoffmann La Roche Fremgangsmåde til arylalkylsulfid
FR2780402B1 (fr) * 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000012477A1 (en) * 1998-08-29 2000-03-09 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
GB9911075D0 (en) * 1999-05-12 1999-07-14 Darwin Discovery Ltd HYdroxamic and carboxylic acid derivatives
GB9911073D0 (en) * 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
BR0108500A (pt) * 2000-02-21 2003-04-29 Astrazeneca Ab Arilpiperazinas e arilpiperidinas e seu uso como agentes inibidores de metaloproteinase
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US6469020B2 (en) 2000-05-15 2002-10-22 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives
US6506773B2 (en) 2000-05-15 2003-01-14 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives
AU778368B2 (en) 2000-05-15 2004-12-02 Darwin Discovery Limited Hydroxamic acid derivatives
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7057057B2 (en) 2002-05-22 2006-06-06 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
CA2486402C (en) * 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
DE10226370B4 (de) 2002-06-13 2008-12-11 Polyic Gmbh & Co. Kg Substrat für ein elektronisches Bauteil, Verwendung des Substrates, Verfahren zur Erhöhung der Ladungsträgermobilität und Organischer Feld-Effekt Transistor (OFET)
DE10233085B4 (de) 2002-07-19 2014-02-20 Dendron Gmbh Stent mit Führungsdraht
US8425549B2 (en) 2002-07-23 2013-04-23 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
WO2004012663A2 (en) 2002-08-01 2004-02-12 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
GB0411562D0 (en) 2004-05-24 2004-06-23 Sterix Ltd Compound
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
US20050277897A1 (en) * 2004-06-14 2005-12-15 Ghannoum Ziad R Handpiece tip
CN101166740B (zh) * 2005-04-25 2010-12-29 诺瓦提斯公司 用作肽脱甲酰基酶(pdf)抑制剂的咪唑并[1,2-a]吡啶衍生物
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
US10000757B2 (en) 2005-05-27 2018-06-19 Ospedale San Raffaele S.R.L. Gene vector
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0604142D0 (en) 2006-03-01 2006-04-12 Sterix Ltd Compound
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
WO2008014430A1 (en) 2006-07-27 2008-01-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
US8088140B2 (en) 2008-05-19 2012-01-03 Mindframe, Inc. Blood flow restorative and embolus removal methods
US11337714B2 (en) 2007-10-17 2022-05-24 Covidien Lp Restoring blood flow and clot removal during acute ischemic stroke
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
US8940003B2 (en) 2008-02-22 2015-01-27 Covidien Lp Methods and apparatus for flow restoration
DK3192874T3 (da) 2008-06-18 2019-12-16 Oxford Biomedica Ltd Virusoprensning
WO2010055413A1 (en) 2008-11-12 2010-05-20 Fondazione Centro San Raffaele Del Monte Tabor Gene vector for inducing transgene-specific immune tolerance
DK2424571T3 (da) 2009-04-30 2020-05-04 Ospedale San Raffaele Srl Genvektor
GB0914767D0 (en) 2009-08-24 2009-09-30 Sterix Ltd Compound
US9039749B2 (en) 2010-10-01 2015-05-26 Covidien Lp Methods and apparatuses for flow restoration and implanting members in the human body
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
EP2953932B1 (en) 2013-02-06 2017-03-01 Merck Patent GmbH Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
AU2014229506B2 (en) 2013-03-11 2017-04-13 Nobesita As Natural lipids containing non-oxidizable fatty acids
US10076399B2 (en) 2013-09-13 2018-09-18 Covidien Lp Endovascular device engagement
EP3613859A1 (en) 2013-10-24 2020-02-26 Ospedale San Raffaele S.r.l. Method
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
GB201418965D0 (da) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
GB201608944D0 (en) 2016-05-20 2016-07-06 Ospedale San Raffaele And Fond Telethon Gene Tharapy
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
DE102017211110A1 (de) 2017-06-30 2019-01-03 Continental Reifen Deutschland Gmbh Verfahren zur Herstellung eines Silans, Verfahren zur Modifizierung einer Kieselsäure mit dem Silan und modifizierte Kieselsäure
GB201807944D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Compositions and methods for haematopoietic stem cell transplantation
GB201807945D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
KR20210030941A (ko) 2018-06-25 2021-03-18 오스페달레 산 라파엘 에스.알.엘. 유전자 요법
CA3115902A1 (en) 2018-10-11 2020-04-16 Ospedale San Raffaele S.R.L Selection by means of artificial transactivators
WO2020148445A1 (en) 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
KR20220139911A (ko) 2020-02-13 2022-10-17 옥스포드 바이오메디카(유케이) 리미티드 렌티바이러스 벡터의 생산
KR20220154734A (ko) 2020-03-13 2022-11-22 옥스포드 바이오메디카(유케이) 리미티드 렌티바이러스 벡터
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
AU2021348257A1 (en) 2020-09-28 2023-03-02 Ludwig Institute For Cancer Research Compositions and methods for increasing stem cell function
AU2021350472A1 (en) 2020-09-28 2023-03-02 Ludwig Institute For Cancer Research Compositions and methods for increasing stem cell function
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
MX2023009036A (es) 2021-02-01 2023-10-30 Epsilen Bio S R L Silenciamiento de genes.
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
BR112023022224A2 (pt) 2021-05-05 2024-02-06 Ludwig Inst For Cancer Res Ltd Urolitina para aumentar função de célula-tronco
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114972D0 (en) 2021-10-19 2021-12-01 Ospedale San Raffaele Srl Gene therapy
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
WO2023209223A1 (en) 2022-04-28 2023-11-02 Ospedale San Raffaele S.R.L. Methods for haematopoietic stem cell transplantation
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
GB202209098D0 (en) 2022-06-21 2022-08-10 Ucl Business Ltd Cyclosporine analogues
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
WO2024079644A1 (en) 2022-10-11 2024-04-18 Fondazione Telethon Ets 3d cell culture methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127722A (en) * 1975-10-02 1978-11-28 Laboratoire L. Lafon Benzhydrylsulphinyl derivatives
DE2804576A1 (de) * 1977-02-15 1978-08-17 Lafon Labor Phenylamidin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
WO1993020047A1 (en) * 1992-04-07 1993-10-14 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
US5698706A (en) * 1995-05-10 1997-12-16 Chiroscience Limited Heterocyclic amides and methods of use
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
ES2183905T3 (es) * 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
EP0871439B1 (en) * 1996-01-02 2004-03-31 Aventis Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
CA2266368A1 (en) * 1996-09-27 1998-04-02 Pharmacia & Upjohn Company .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors
WO1998039316A1 (en) * 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds

Also Published As

Publication number Publication date
DE69729007T2 (de) 2005-04-07
AU730464B2 (en) 2001-03-08
CZ297278B6 (cs) 2006-10-11
PT968182E (pt) 2004-08-31
EP0968182B1 (en) 2004-05-06
NO990543L (no) 1999-04-06
NO990543D0 (no) 1999-02-05
WO1998005635A1 (en) 1998-02-12
BR9711027A (pt) 1999-08-17
ATE266000T1 (de) 2004-05-15
PL193829B1 (pl) 2007-03-30
CA2263154A1 (en) 1998-02-12
DE69729007D1 (de) 2004-06-09
NO314452B1 (no) 2003-03-24
CZ36899A3 (cs) 1999-07-14
JP2000517297A (ja) 2000-12-26
AU3856497A (en) 1998-02-25
PL331598A1 (en) 1999-08-02
KR20000029858A (ko) 2000-05-25
ES2217425T3 (es) 2004-11-01
US6118001A (en) 2000-09-12
EP0968182A1 (en) 2000-01-05
CN1227540A (zh) 1999-09-01

Similar Documents

Publication Publication Date Title
DK0968182T3 (da) Hydroxam- og carboxylsyrederivater med MMP- og TNF-inhiberende aktivitet
NO961888L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
BR9908280A (pt) Inibidores de enzimas de fosfolipase
IS4955A (is) Tálmar gegn frumusamloðun
UY27972A1 (es) Derivados de hidantoína
ATE219058T1 (de) Alpha-substituierte arylsulphonamidohydroxamsaüre als tnf-alpha und matrix-metalloproteinase- inhibitoren
DK0821671T3 (da) Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
PL331369A1 (en) Thiosulphonic metaloprotease inhibitors
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
NO20002440L (no) Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
EE200000093A (et) Agrekanaasi ja maatriksmetalloproteinaaside uudsed inhibiitorid artriidi käitlemiseks
IL123431A0 (en) Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (MMP) and/or tumour necrosis factor (TNF)
NO981520D0 (no) Tiosubstituerte peptider som inhibitorer for metalloproteinaser og TNF-frigjöring
TR199802638T2 (xx) Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
WO2000075106A3 (en) Matrix metalloproteinase inhibitors and method of using same
EE03745B1 (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
BR0011801A (pt) Inibidores de benzamida substituìda para 3c protease de rinovìrus
ATE237630T1 (de) Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
NO20003828L (no) 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinase inhibitorer
DE69608683D1 (de) Analytisches und therapeutisches mittel
DE69821228D1 (de) Selektive mmp inhibitoren mit verringerten nebenwirkungen
ATE286892T1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
DK1096951T3 (da) Anvendelse af bromelainproteaser til inhiberingen af blodkoaguleringen
BR9803717A (pt) ácidos indol-2-carbocìlicos substituìdos como inibidores de glucosil transferase.